What it is
Thymalin is a polypeptide complex isolated from thymus tissue. That sentence carries the most important fact in this entry, and it is the one that disappears whenever the compound is listed in a table beside single peptides: it is a mixture, not a molecule.
The thymus is the organ where T cells mature, and extracting its peptides in the hope of restoring immune function is an old idea. Thymalin came out of that idea in the Soviet Union from the 1970s, at the institution that became the St Petersburg Institute of Bioregulation and Gerontology — the same programme that later produced the very short synthetic bioregulators such as the telomere peptide Epitalon and Cartalax.
It has been licensed and used clinically in Russia and neighbouring states for decades, as an immunocorrector: given after serious infections, after chemotherapy, and to older patients with diminished immune function.
How it differs from thymosin alpha-1
These two get treated as the same thing, and they are not.
| Thymosin alpha-1 | Thymalin | |
|---|---|---|
| What it is | One peptide, 28 amino acids, defined sequence | A complex of polypeptides from thymus tissue |
| Manufacture | Chemical synthesis, identical every batch | Extraction from calf thymus |
| Composition | Fully specified | Being worked out; 2023 research focuses on the dipeptides KE and EW |
| Registered trials | Yes, internationally | None |
Thymosin alpha-1, a defined single molecule has an international evidence base. Thymalin is a preparation with a clinical tradition. Both are legitimate objects of study; a claim about one is simply not evidence about the other.
The distinction also affects what can be known. A synthetic peptide is the same substance in every vial. An extract is defined by its process, and consistency between batches becomes a research question in its own right — which is exactly why a 2023 paper in the International Journal of Molecular Sciences set out to identify which fragments of the mixture, specifically the dipeptides KE (Lys-Glu) and EW (Glu-Trp), are doing the work.
The numbers, and what they do not settle
PubMed indexed 293 records for Thymalin on 2026-09-11, of which 195 carry a human tag. At roughly two in three, that is the highest human proportion this library has measured for any compound — higher than LL-37's unusual seven-in-ten-of-a-much-larger-number, and far above the norm here, where most compounds' literatures are dominated by animal work.
ClinicalTrials.gov held zero registrations.
That combination has a specific meaning in this case, and it is neither of the two meanings this library has previously had to explain. It is not a literature that measures the body's own molecule instead of administering anything, as with MOTS-c. It is not a literature that predates the registry, as with GHRP-6 — this work is ongoing, with papers from 2022, 2023 and 2024.
It is a parallel evidence system. The clinical work is published in Russian-language journals — Advances in Gerontology, Bulletin of Experimental Biology and Medicine, Problems of Endocrinology — which have never required registration on an American database. Decades of clinical use, 195 human-tagged papers, and not one registry entry.
This is a real limitation, not a technicality of paperwork. Registration is what fixes a trial's design and its endpoints in public before the results are known, and it is the main defence against a literature that looks positive because the negative studies were never published. Without it, a positive body of work cannot be distinguished from a selectively reported one — however large it is.
The longevity claim, and where it comes from
The strongest claim made for Thymalin is that it extends human life. It rests on essentially one source.
A 2003 paper in Neuro Endocrinology Letters by Khavinson and Morozov — titled, without hedging, Peptides of pineal gland and thymus prolong human life — reports a clinical assessment of thymic (Thymalin) and pineal (Epithalamin) preparations in 266 elderly and older people followed for 6 to 8 years, with the preparations given only during the first 2 to 3 years of observation. The authors report normalisation of cardiovascular, endocrine, immune and nervous system indices, and a 2.0- to 2.4-fold decrease in acute respiratory disease incidence.
Two things should be said about it, and both are true at once.
The design is genuinely interesting: a treatment period followed by years of continued follow-up is how you would test whether an intervention has lasting effects, and few longevity claims anywhere are supported by anything with that shape.
And the study was conducted by the institutes that developed the preparations, published in a journal outside the main clinical literature, never registered, and — as far as this library has been able to establish — never independently replicated. A result of that size, reported once, by its own developers, is a reason to keep looking. It is not a reason to conclude.
The most checkable finding in the record
Amid a lot of general clinical description, one recent result is specific enough to be useful. A 2020 study in the Bulletin of Experimental Biology and Medicine reports that Thymalin stimulated the differentiation of human CD117-positive haematopoietic stem cells into mature CD28-positive T lymphocytes, and proposes that as the mechanism behind its effect on immunity.
That is a named cell population, a named surface marker, and a testable claim about human cells — the kind of statement another laboratory can check. For a preparation usually described in terms like "regulates the functions of the immune system", it is the most concrete thing in the file.
Where it stands
There is no US approval. DailyMed and Drugs@FDA returned no product record on 2026-09-11; Thymalin has never been submitted. It occupies the same regulatory position as the licensed single-molecule thymosin alpha-1 — licensed and used elsewhere, never through the American process — and this library carries entries for both for the same reason: readers arrive with the name, and the useful answer is what kind of thing it is.
Related reading
Thymosin alpha-1 for the single-molecule counterpart with an international evidence base. Epitalon and the cartilage tetrapeptide for the short synthetic peptides from the same St Petersburg programme — with Cartalax showing what that tradition's thinnest files look like, against this one's fullest. For the wider category, see peptides for immunity and peptides for longevity.